High-MET status in non-small cell lung tumors correlates with receptor phosphorylation but not with the serum level of soluble form. (November 2016)

• Record Type: Journal Article
• Authors: Copin, Marie-Christine; Lesaffre, Marie; Berbon, Mélanie; Doublet, Louis; Leroy, Catherine; Tresch, Emmanuelle; Porte, Henri; Vicogne, Jérôme; B. Cortot, Alexis; Dansin, Eric; Tulasne, David
• Is Part Of: Lung cancer. Volume 101(2016)
• Page Start: 59
• Page End: 67
• Publication Date: 2016-11
• Subjects: Lung cancer -- MET -- Receptor tyrosine kinase -- Hepatocyte growth factor/scatter factor -- Phosphorylation -- Proteolytic cleavages; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2016.09.009
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: The receptor tyrosine kinase MET is considered as a promising target in lung cancer. Serum level of soluble MET fragment is not indicative of the amount of MET in the tumor. Tumor displaying a high MET level also displayed receptor phosphorylation. Abstract: Objectives: The receptor tyrosine kinase MET is essential to embryonic development and organ regeneration. Its deregulation is associated with tumorigenesis. While MET gene amplification and mutations leading to MET self-activation concern only a few patients, a high MET level has been found in about half of the non-small cell lung cancers (NSCLCs) tested. How this affects MET activation in tumors is unclear. Also uncertain is the prognostic value, in cancer, of a phenomenon well described in cell models: MET shedding, i.e. its cleavage by membrane proteases leading to release of a soluble fragment into the medium. Materials and methods: A prospective cohort of 39 NSCLC patients was constituted at diagnosis or soon after. Normal tissues, tumor tissues, and blood samples were obtained. This allowed, for the same patient, synchronous determination of (i) the MET level in the tumor, (ii) receptor phosphorylation, and (iii) the concentration of soluble MET fragment (sMET) in the serum. Results: After confirming the adequacy of an ELISA for measuring the serum level of sMET, we found no correlation between this level and the concentration of MET in tumors, as evaluated by immunohistochemistry and western blotting. Nevertheless, all but one tumor displaying a high MET level also displayed receptor phosphorylation, restricted to a small number of tumor cells. Conclusion: Our results thus demonstrate that the serum level of sMET is not indicative of the amount of MET present in the tumor cells and cannot be used as a biomarker for therapeutic purposes. However, MET scoring of tumor biopsies could be a first step prior to determination of MET receptor activation in high-MET tumors.